Sanofi moved to stop its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis found the antibody was unlikely to provide sufficient efficacy, despite no safety concerns reported. The decision also raises new questions for the complement-inhibitor approach in CIDP after earlier setbacks in the class and amid competitive pressure. In parallel, Gilead pulled the plug on Trodelvy (sacituzumab govitecan) plus Keytruda in the Phase 3 Evoke-03 (Keynote-D46) first-line PD-L1-high non-small cell lung cancer trial. The study missed progression-free survival at final analysis, and overall survival was deemed unlikely to achieve statistical significance. Taken together, the two decisions underscore how quickly late-stage evidence can shift treatment landscapes in both autoimmune neurology and oncology, and may redirect attention to next-generation assets and competitors as 2026 regulatory timelines tighten.